Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Sodium Phosphate

FDA-approved product (injectable, injection), marketed as Hydrocortone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Asthma
  • Atopic eczema
  • Bursitis
  • Cancer
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Exanthem
  • Eye inflammation
  • Hemorrhoid
  • Herpes Labialis
  • and 19 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis

    NCT01941589 · start 2013-09

    Registered record
    Registry ID
    NCT01941589
    Conditions
    Ulcerative Colitis
    Interventions
    oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone; corticosteroids only
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2021-04
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    Interventionoral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone; corticosteroids only
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

    NCT02153762 · start 2013-04

    Registered record
    Registry ID
    NCT02153762
    Conditions
    Atopic Dermatitis
    Interventions
    Locoid Lipocream; Hylatopic Plus
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionLocoid Lipocream; Hylatopic Plus
    PhaseNot applicable
    Registry statusCompleted

  • Laser Therapy on Neck Pain in Adolescents

    NCT01849913 · start 2013-02

    Registered record
    Registry ID
    NCT01849913
    Conditions
    Neck Pain
    Interventions
    Laser; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2014-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeck Pain
    InterventionLaser; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

    NCT01735617 · start 2012-12

    Registered record
    Registry ID
    NCT01735617
    Conditions
    Endocrine Disease; Adrenal Insufficiency; Congenital Adrenal Hyperplasia
    Interventions
    Hydrocortisone Modified Release Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocrine Disease; Adrenal Insufficiency; Congenital Adrenal Hyperplasia
    InterventionHydrocortisone Modified Release Capsules
    PhasePhase 2
    Registry statusCompleted

  • Corticosteroids for the Prevention of Atrial Fibrillation After Cardiac Surgery

    NCT00442494 · start 2012-10

    Registered record
    Registry ID
    NCT00442494
    Conditions
    Atrial Fibrillation
    Interventions
    intravenous hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2012-10
    Completion
    2012-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    Interventionintravenous hydrocortisone
    PhaseNot applicable
    Registry statusTerminated

  • Fludrocortisone for Sudden Hearing Loss

    NCT01186185 · start 2012-08

    Registered record
    Registry ID
    NCT01186185
    Conditions
    Hearing Loss, Sensorineural
    Interventions
    Fludrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2012-08
    Completion
    2016-03
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHearing Loss, Sensorineural
    InterventionFludrocortisone
    PhaseEarly phase 1
    Registry statusTerminated

  • Peri-Operative Steroid Management in Patients

    NCT02084134 · start 2012-03

    Registered record
    Registry ID
    NCT02084134
    Conditions
    Pituitary Adenoma; Pituitary Diseases
    Interventions
    hydrocortisone; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-03
    Completion
    2016-12-31
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Adenoma; Pituitary Diseases
    Interventionhydrocortisone; dexamethasone
    PhaseNot applicable
    Registry statusCompleted

  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

    NCT02883049 · start 2012-02-29

    Registered record
    Registry ID
    NCT02883049
    Conditions
    B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia; Testicular Leukemia
    Interventions
    Clofarabine; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin Hydrochloride; Dexamethasone; Doxorubicin Hydrochloride; Etoposide; Hydrocortisone Sodium Succinate; Laboratory Biomarker Analysis; Leucovorin Calcium; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Radiation Therapy; Thioguanine; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-02-29
    Completion
    2026-03-31
    Enrolment
    5,949

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia; Testicular Leukemia
    InterventionClofarabine; Cyclophosphamide; Cytarabine; Dasatinib +14 more
    PhasePhase 3
    Registry statusCompleted

  • Fibrin Monomer Compared With Hemostatic Sponge in the Integrity of the Graft During Tympanoplasty

    NCT02120651 · start 2012-01

    Registered record
    Registry ID
    NCT02120651
    Conditions
    Tympanic Membrane Perforation
    Interventions
    Fibrin monomer; Hemostatic sponge
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTympanic Membrane Perforation
    InterventionFibrin monomer; Hemostatic sponge
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face

    NCT01024374 · start 2010-04

    Registered record
    Registry ID
    NCT01024374
    Conditions
    Seborrheic Dermatitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-04
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeborrheic Dermatitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    NCT00873093 · start 2009-03

    Registered record
    Registry ID
    NCT00873093
    Conditions
    B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Lymphoblastic Lymphoma; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia
    Interventions
    L-asparaginase; doxorubicin hydrochloride; therapeutic hydrocortisone; vincristine sulfate; cytarabine; prednisone; bortezomib; pegaspargase; methotrexate; etoposide phosphate; cyclophosphamide; filgrastim; leucovorin calcium; laboratory biomarker analysis; High Dose MTX
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2014-09
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma +4 more
    InterventionL-asparaginase; doxorubicin hydrochloride; therapeutic hydrocortisone; vincristine sulfate +11 more
    PhasePhase 2
    Registry statusCompleted

  • Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer

    NCT00473083 · start 2009-01

    Registered record
    Registry ID
    NCT00473083
    Conditions
    Rash
    Interventions
    Minocycline; Clindamycin 2% in hydrocortisone 1% lotion; Erlotinib; Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-01
    Completion
    2013-08
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRash
    InterventionMinocycline; Clindamycin 2% in hydrocortisone 1% lotion; Erlotinib; Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
    PhasePhase 2
    Registry statusCompleted

  • Septic Shock em Steroids

    NCT01047670 · start 2008-05

    Registered record
    Registry ID
    NCT01047670
    Conditions
    Mechanical Ventilation; Mortality
    Interventions
    Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMechanical Ventilation; Mortality
    InterventionHydrocortisone
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease

    NCT00507832 · start 2007-04

    Registered record
    Registry ID
    NCT00507832
    Conditions
    Prurigo Nodularis
    Interventions
    Pimecrolimus; Hydrocortisone; Pimecrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-04
    Completion
    2009-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrurigo Nodularis
    InterventionPimecrolimus; Hydrocortisone; Pimecrolimus
    PhasePhase 2
    Registry statusCompleted

  • Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery

    NCT00415701 · start 2006-11

    Registered record
    Registry ID
    NCT00415701
    Conditions
    Coronary Artery Disease; Mitral Valve Regurgitation
    Interventions
    Etomidate; Propofol; Hydrocortisone; NaCl 0.9%; Tetracosactin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-11
    Completion
    2009-12
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Mitral Valve Regurgitation
    InterventionEtomidate; Propofol; Hydrocortisone; NaCl 0.9% +1 more
    PhasePhase 4
    Registry statusCompleted